EUVIMEDEUVIMED entdecken
Crossref

HBsAg Isoforms as Innovative Biomarkers in Predicting Virological Response to Bulevirtide in Patients With Chronic Hepatitis D

Stefano D'Anna, Romina Salpini, Elisabetta Degasperi iD, Lorenzo Piermatteo, Floriana Facchetti, Dana Sambarino, Giulia Torre, Marta Borghi, Maria Paola Anolli, Sara Monico, Valentina Svicher iD, Pietro Lampertico iD

Liver International · 2025-05 · 45 (5)

DOI: 10.1111/liv.70094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 28.04.2025. Verfasst von Stefano D'Anna und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Rome Tor Vergata, Rome, Italy. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Hepatitis D, Chronic, Antiviral Agents, Liver Cirrhosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: HORIZON EUROPE European Research Council, Ministero dell'Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims HDV exploits HBV surface‐protein (HBsAg) for entering into hepatocytes. HBsAg consists of 3 isoforms: Large‐ (L‐HBs, predominantly present in virions and mediating binding to NTCP‐receptor), Middle‐ (M‐HBs) and Small‐HBsAg (S‐HBs). Here, we investigated the kinetics of HBs isoforms under bulevirtide treatment (BLV).

Methods

67 consecutive patients with HDV‐related compensated cirrhosis starting BLV 2 mg/day were enrolled. L‐HBs, M‐HBs and S‐HBs were quantified by ad‐hoc ELISAs in baseline and week 48 (W48) samples.

Results

At baseline, median (IQR) HDV‐RNA was 5.1 (4.3–5.7) log IU/mL while median (IQR) S‐HBs, M‐HBs and L‐HBs levels were 3801 (1401–7462), 743 (211–1710) and 5 (1–13) ng/mL. At W48, virological responses (VR) were observed in 72% (48/67) of patients, while 25.4% (17/67) achieved undetectable HDV‐RNA (11/17 with ALT‐normalisation). A decline of S‐HBs, M‐HBs and L‐HBs levels was observed in 51%, 63% and 31% of patients (median [IQR] decline: 961 [461–1985], 258 [68–626] and 4 [2‐12] ng/mL). Notably, patients with undetectable HDV‐RNA at W48 had baseline L‐HBs and S‐HBs levels lower than patients not achieving this end‐point (1 [0.3–7] vs. 6 [2‐13] ng/mL, p = 0.04 and 1570 [369–5185] vs. 4015 [1646–8687] ng/mL, p = 0.002). By AUROC, patients with baseline L‐HBs < 3 ng/mL or S‐HBs < 3400 ng/mL were more likely to achieve HDV‐RNA undetectability at W48 (39.3% vs. 15.8%, p = 0.04 and 38.7% vs. 13.9%, p = 0.03). Furthermore, the combination of pre‐treatment L‐HBs < 3 ng/mL + HDV‐RNA < 5logIU/mL and S‐HBs < 3400 ng/mL + HDV‐RNA < 5logIU/mL was the best predictor for achieving undetectable HDV‐RNA at W48 (56.3% vs. 15.7%, p = 0.002 and 60% vs. 11%, p < 0.001).

Conclusions

Quantification of L‐HBs and of S‐HBs, along with HDV‐RNA, may reflect the burden of circulating infectious virions in HBV/HDV co‐infection, providing a promising tool to identify patients more likely to respond to BLV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Surface AntigensHepatitis D, ChronicAntiviral AgentsLiver CirrhosisHumansMaleFemaleMiddle AgedBiomarkersHepatitis Delta VirusAdultProtein IsoformsRNA, ViralAgedViral LoadNucleic AcidsPolymers

Stichwörter der Autor:innen

HBsAg isoformsbulevirtide treatmenthepatitis delta virusnon‐invasive biomarkersvirological response

Substanzen

BiomarkersHepatitis B Surface AntigensAntiviral AgentsProtein IsoformsREP 2139RNA, ViralNucleic AcidsPolymers

Autor:innen und Institutionen

  • Department of Biology, University of Rome Tor Vergata, Rome, Italy.
  • Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • CRC "A. M. and A. Migliavacca" Center for Liver Disease, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

ORCID-Profile: Elisabetta Degasperi, Valentina Svicher, Pietro Lampertico

Förderung

  • HORIZON EUROPE European Research Council
  • Ministero dell'Università e della Ricerca

Zitieren

APA

D'Anna, S., Salpini, R., Degasperi, E., Piermatteo, L., Facchetti, F., Sambarino, D., Torre, G., Borghi, M., Anolli, M. P., Monico, S., Svicher, V., & Lampertico, P. (2025). HBsAg Isoforms as Innovative Biomarkers in Predicting Virological Response to Bulevirtide in Patients With Chronic Hepatitis D. Liver International, 45(5). https://doi.org/10.1111/liv.70094

Vancouver

D'Anna S, Salpini R, Degasperi E, Piermatteo L, Facchetti F, Sambarino D, et al. HBsAg Isoforms as Innovative Biomarkers in Predicting Virological Response to Bulevirtide in Patients With Chronic Hepatitis D. Liver International. 2025;45(5). doi:10.1111/liv.70094

BibTeX
@article{DAnna2025,
  author = {D'Anna, Stefano and Salpini, Romina and Degasperi, Elisabetta and Piermatteo, Lorenzo and Facchetti, Floriana and Sambarino, Dana and Torre, Giulia and Borghi, Marta and Anolli, Maria Paola and Monico, Sara and Svicher, Valentina and Lampertico, Pietro},
  title = {HBsAg Isoforms as Innovative Biomarkers in Predicting Virological Response to Bulevirtide in Patients With Chronic Hepatitis D},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {5},
  doi = {10.1111/liv.70094}
}
Kostenlos starten →